Kakhnovskiĭ I M, Sivkov S I, Gavrilova E N, Belaia O L, Sivkov A S, Markova Z S, Markov I E, Gaĭdamakina N E
Klin Med (Mosk). 1998;76(9):52-4.
The aim of the study was to assess prestarium effects on central and renal hemodynamics, blood lipids in hypertensive subjects. Prestarium was given in a daily dose 4-6 mg to 30 patients with essential hypertension stage II free of cardiac decompensation and renal failure. Echocardiography, tetrapolar chest rheoplethysmography with assessment of hemodynamics, radionuclide tracing of renal blood flow, tests for cholesterol and blood electrolytes were made before treatment, on treatment weeks 2-3 and 12. It was found that prestarium lowers blood pressure and total peripheral vascular resistance. Myocardial conductivity was not affected, whereas renal circulation activated. Low-density lipoproteins cholesterol fell. No significant changes in electrolytes were seen. The drug was well tolerated. In view of good clinical effect and tolerance prestarium is recommended for treatment of essential hypertension stage II in the absence of cardiac decompensation and renal dysfunction.
该研究的目的是评估普司他定对高血压患者中枢和肾脏血流动力学以及血脂的影响。给予30例无心脏失代偿和肾衰竭的II期原发性高血压患者每日剂量为4 - 6毫克的普司他定。在治疗前、治疗第2 - 3周和第12周进行了超声心动图检查、用于评估血流动力学的四极胸血流容积描记法、肾血流放射性核素追踪、胆固醇和血液电解质检测。结果发现，普司他定可降低血压和总外周血管阻力。心肌传导性未受影响，而肾循环得到激活。低密度脂蛋白胆固醇下降。电解质未见明显变化。该药物耐受性良好。鉴于良好的临床效果和耐受性，推荐在无心脏失代偿和肾功能不全的情况下，使用普司他定治疗II期原发性高血压。
